All In Biotech

Drug Trial Radar · NCT06764615

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

A Phase 2, Open-Label Extension Trial to Evaluate the Long-term Safety and Tolerability of Oral Zasocitinib (TAK-279) in Participants With Moderately to Severely Active Ulcerative Colitis and Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

May 28, 2025

Primary completion

Dec 30, 2029

Study completion Dec 30, 2029

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jan 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension of the parent studies, TAK-279-CD-2001 (NCT06233461), TAK-279-UC-2001 (NCT06254950) and TAK-279-CD-2003 (NCT07403968). This means that participants who responded to treatment with TAK-279 in either of the parent studies may be able to continue to benefit from the treatment in this study. The main aim of this study is to find out how safe TAK-279 is for long term use and to check if it reduces bowel inflammation and symptoms when used for a longer period of time in adults with moderately to severely active UC or CD. The participants will be treated with TAK-279 for up to 3 years (156 weeks). During the study, participants will visit their study clinic around 15 times.

Conditions

  • Crohn's Disease
  • Ulcerative Colitis

Interventions

  • ZasocitinibDrug

    Zasocitinib capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)Time frame: From start of study drug administration up to Week 160 (current study)
  2. All Cohorts: Number of Participants With Clinically Significant Changes in Vital Sign ValuesTime frame: From start of study drug administration up to Week 160 (current study)
  3. All Cohorts: Number of Participants With Clinically Significant Changes in Clinical Laboratory ValuesTime frame: From start of study drug administration up to Week 160 (current study)
  4. Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) ValuesTime frame: At Day 1 and Week 156 (current study)

Locations

16 sites in 8 countries. Site status is shown where the registry gives one.

  • Woodholme Gastroenterology Associates

    Glen Burnie, Maryland · Recruiting

  • Tyler Research Institute, LLC

    Tyler, Texas · Recruiting

  • Chongqing General Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangdong, Guangdong, China · Recruiting

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Renji Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Hepato-Gastroenterologie HK s.r.o.

    Hradec Králové, Czechia · Recruiting

  • Pannonia Maganorvosi Centrum

    Budapest, Hungary · Recruiting

  • St. Antonius Ziekenhuis

    Tilburg, North Brabant, Netherlands · Recruiting

  • Centrum Medyczne MedykSp. z o.o. Sp. K.

    Lublin, Poland · Recruiting

  • Twoja Przychodnia - Szczecinskie Centrum Medyczne

    Szczecin, Poland · Recruiting

  • WIP Warsaw IBD Point Profesor Kierkus

    Warsaw, Poland · Recruiting

  • Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj

    Torun, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting

  • Endomed

    Košice, Slovakia · Recruiting

  • Inje University Haeundae Paik Hospital

    Haeundae, Busan Gwangyeogsi, South Korea · Recruiting

  • Yonsei University Wonju Severance Christian Hospital

    Wŏnju, Gangwon-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.